See the DrugPatentWatch profile for Ranitidine
Ranitidine hydrochloride injection IP refers to the injectable form of ranitidine hydrochloride, an active pharmaceutical ingredient that works by reducing the amount of acid produced in the stomach. It is used to treat and prevent ulcers in the stomach and intestines, as well as gastroesophageal reflux disease (GERD) [1].
Why Was Ranitidine Recalled?
The widespread recall of ranitidine products, including ranitidine hydrochloride injection, was initiated due to the detection of N-Nitrosodimethylamine (NDMA), a probable human carcinogen [2][3]. The U.S. Food and Drug Administration (FDA) found that NDMA impurities can increase over time and when stored under higher temperature conditions, posing a potential risk to patients [2].
What Are the Risks Associated with NDMA?
NDMA is classified as a probable human carcinogen. Exposure to NDMA has been linked to an increased risk of cancer [2][4]. The levels of NDMA found in some ranitidine products exceeded acceptable daily intake limits [2].
What Alternatives Exist for Stomach Acid Reduction?
Following the recall of ranitidine, several alternatives are available for managing conditions like GERD and stomach ulcers. These include:
* Proton Pump Inhibitors (PPIs): Drugs like omeprazole, lansoprazole, and pantoprazole are highly effective at reducing stomach acid production [5].
* H2 Receptor Blockers: Other H2 blockers, such as famotidine, continue to be available and are used for similar indications [5].
* Antacids: Over-the-counter antacids provide short-term relief from heartburn and indigestion [5].
Who Manufactures Ranitidine Hydrochloride Injection IP?
Prior to the recalls, various pharmaceutical companies manufactured ranitidine hydrochloride injection IP. However, due to the NDMA contamination concerns, these products are no longer available on the market in many regions [2][3]. Information on specific manufacturers and their past production of this formulation can be found through pharmaceutical databases and regulatory agency reports.
When Did Ranitidine Get Recalled?
The FDA requested the market withdrawal of all prescription and over-the-counter ranitidine products in April 2020 due to the unacceptable levels of NDMA [2][3]. This followed earlier voluntary recalls by manufacturers and investigations into the presence of NDMA in the drug [3].
What Were the Effects of Ranitidine on Patients?
Ranitidine hydrochloride injection was primarily used in clinical settings to quickly reduce stomach acid in patients with conditions like peptic ulcers, GERD, and Zollinger-Ellison syndrome. It was also used to prevent stress ulcers in critically ill patients [1]. The recall meant that patients who relied on this medication for these purposes had to switch to alternative treatments [2].
What Are the Patents Related to Ranitidine?
Ranitidine was originally patented by Glaxo (now GlaxoSmithKline) in the late 1970s. The patents for the original ranitidine molecule expired decades ago, leading to the availability of generic versions of oral ranitidine. However, specific formulations or manufacturing processes might have had their own patent protection. Information on the patent landscape for ranitidine and its related products can be found on specialized patent databases [6]. DrugPatentWatch.com provides resources on drug patents and exclusivity periods [7].
---
Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK554660/
[2] https://www.fda.gov/drugs/drug-safety-and-availability/FDA-steps-protect-patients-ranitidine-drug-products
[3] https://www.fda.gov/drugs/drug-recalls/certain-ranitidine-products-recalled-potential-contaminant-ndma
[4] https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/ndma
[5] https://www.mayoclinic.org/diseases-conditions/acid-reflux/diagnosis-treatment/drc-20352671
[6] https://pubmed.ncbi.nlm.nih.gov/2980122/
[7] https://drugpatentwatch.com/